Wize Pharma

About

Funding history · 3 rounds · $5.2M total

Headcount over time

Q&A

What was the acquisition status of Wize Pharma?

Wize Pharma was acquired by Mawson Infrastructure Group in March 2021 for $51.4 million. Following the acquisition, the company changed its name to Mawson Infrastructure Group Inc. and shifted its focus to Bitcoin mining.

What was Wize Pharma's primary focus before its acquisition?

Wize Pharma was a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES), Conjunctivochalasis (CCH), and Sjögren's syndrome.

What was the total amount raised by Wize Pharma through funding rounds?

Wize Pharma raised a total of $8 million USD through various funding rounds.

When did Wize Pharma complete its Phase IV study for LO2A in treating dry eye syndrome in Sjögren's syndrome patients?

Wize Pharma completed its Phase IV study of LO2A for the treatment of dry eye syndrome in patients with Sjögren's syndrome in May 2020, with positive topline results announced in November 2020.

Did Wize Pharma engage in any strategic transactions with other companies?

Yes, Wize Pharma completed a strategic transaction with Bonus BioGroup in February 2020.

What was Wize Pharma's employee count at the time of its acquisition?

Wize Pharma had 1-10 employees at the time of its acquisition.

What was the purpose of the joint venture between Wize Pharma and Cannabics Pharmaceuticals?

In February 2019, Wize Pharma signed a joint venture with Cannabics Pharmaceuticals to research and develop cannabinoid formulations for treating ophthalmic conditions.

Where was LO2A, Wize Pharma's key drug, registered and marketed?

LO2A was registered and marketed in Germany and Switzerland for DES, in Hungary for DES, CCH, and Sjögren's, and in the Netherlands for DES and Sjögren's.

Team · 1

Gideon Stein

Founder · Co-founder & Medical Consultant

Sectors & technology

Tags